Takeda
Vedolizumab
Crohn's Disease
Countdown
336days
Phase 3 readout · Jun 8, 2027
What's at stake
Phase 3 trial results for Vedolizumab in Crohn's Disease are due Jun 8, 2027. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· ClinicalTrials.gov
verified 15h ago
“CT.gov NCT06227910: Phase 3 trial, sponsor Takeda, drug Vedolizumab. Primary completion date 2027-06-08 (estimated).”